(PC) Legare v. Cryer

CourtDistrict Court, E.D. California
DecidedSeptember 4, 2019
Docket1:18-cv-01474
StatusUnknown

This text of (PC) Legare v. Cryer ((PC) Legare v. Cryer) is published on Counsel Stack Legal Research, covering District Court, E.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
(PC) Legare v. Cryer, (E.D. Cal. 2019).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 EASTERN DISTRICT OF CALIFORNIA 10 11 JAMES PAUL LEGARE, Case No. 1:18-cv-01474-BAM (PC) 12 Plaintiff, SCREENING ORDER GRANTING PLAINTIFF LEAVE TO AMEND 13 v. (ECF No. 1) 14 C. CRYER, et al.,

15 Defendants. THIRTY-DAY DEADLINE 16 17 18 Plaintiff James Paul Legare (“Plaintiff”) is a state prisoner proceeding pro se and in forma 19 pauperis in this civil rights action under 42 U.S.C. § 1983. Plaintiff’s complaint, filed on October 20 24, 2018, is currently before the Court for screening. (ECF No. 1.) 21 I. Screening Requirement and Standard 22 The Court is required to screen complaints brought by prisoners seeking relief against a 23 governmental entity and/or against an officer or employee of a governmental entity. 28 U.S.C. 24 § 1915A(a). Plaintiff’s complaint, or any portion thereof, is subject to dismissal if it is frivolous or 25 malicious, if it fails to state a claim upon which relief may be granted, or if it seeks monetary relief 26 from a defendant who is immune from such relief. 28 U.S.C. §§ 1915A(b). 27 A complaint must contain “a short and plain statement of the claim showing that the pleader 28 1 is entitled to relief . . . .” Fed. R. Civ. P. 8(a)(2). Detailed factual allegations are not required, but 2 “[t]hreadbare recitals of the elements of a cause of action, supported by mere conclusory statements, 3 do not suffice.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citing Bell Atlantic Corp. v. Twombly, 4 550 U.S. 544, 555 (2007)). While a plaintiff’s allegations are taken as true, courts “are not required 5 to indulge unwarranted inferences.” Doe I v. Wal-Mart Stores, Inc., 572 F.3d 677, 681 (9th Cir. 6 2009) (internal quotation marks and citation omitted). 7 To survive screening, Plaintiff’s claims must be facially plausible, which requires sufficient 8 factual detail to allow the Court to reasonably infer that each named defendant is liable for the 9 misconduct alleged. Iqbal, 556 U.S. at 678 (quotation marks omitted); Moss v. U.S. Secret Serv., 10 572 F.3d 962, 969 (9th Cir. 2009). The sheer possibility that a defendant acted unlawfully is not 11 sufficient, and mere consistency with liability falls short of satisfying the plausibility standard. 12 Iqbal, 556 U.S. at 678 (quotation marks omitted); Moss, 572 F.3d at 969. 13 II. Allegations in Complaint 14 Plaintiff is currently housed at the California Institution for Men in Chino, California. The 15 events in the complaint are alleged to have occurred while Plaintiff was housed at the California 16 Substance Abuse and Treatment Facility (“CSATF”) in Coalinga, California. Plaintiff names the 17 following defendants: (1) C. Cryer, Chief Executive Officer; (2) S. Gates, Chief, Health Care 18 Appeals Branch-Sacramento; and (3) Does 1 through 5, CSATF medical/health care providers. 19 Claim I 20 In Claim I, Plaintiff alleges that in July 2017, he was prescribed Oxcarbazepine (“Trileptal”) 21 for pain management. Soon after taking Trileptal, Plaintiff began to suffer serious side effects. On 22 August 1, 2017, Plaintiff submitted a CDCR 7362 medical request complaining of serious side 23 effects from Trileptal and requesting that Trileptal be discontinued and another pain management 24 medication be issued. Plaintiff complains that his complaints and request were met with deliberate 25 indifference and no corrective treatment was provided by Doe Defendants. 26 By August 15, 2017, Plaintiff could no longer withstand the side effects and refused to take 27 Trileptal. As a result of his refusal, Doe Defendants issued Plaintiff a CDCR 128B record, which 28 was negatively addressed by the Parole Board Commissioners on August 6, 2017. 1 From August 15, 2017 to September 17, 2017, Doe Defendants provided Plaintiff with no 2 care or treatment to relieve Plaintiff’s groin pain. On September 17, 2017, acetaminophen 3 (“Mapap”) was prescribed, which barely reduced the pain levels Plaintiff repeatedly reported to 4 Doe Defendants. Plaintiff believes Mapap is nothing more than a fever reducer, which Doe 5 Defendants knew and used to intentionally cause Plaintiff suffering. 6 On October 13, 2017, Plaintiff filed a Health Care Administrative Appeal. 7 On December 20, 2017, Defendant Cryer issued CSATF’s institutional level response. 8 Plaintiff contends that the response is deflective, callous and with self-serving verbiage that 9 incorporates false statements that at no time was Plaintiff without pain medication. Additionally, 10 Defendant Cryer stated that Trileptal was approved by the Food and Drug Administration (“FDA”) 11 for use as a pain medication. He also stated that Plaintiff’s primary care provider could not 12 prescribe Trileptal for use as a pain medication if it was not approved for such use. 13 On January 10, 2018, Plaintiff advanced his medical appeal to Headquarters Level for 14 review. In his appeal, Plaintiff posed specific questions to Defendant Gates to clarify Defendant 15 Cryer’s statement that Trileptal was an authorized FDA pain management medication. 16 On April 26, 2018, Defendant Gates issued the Headquarters Level Response to Plaintiff’s 17 medical appeal. Defendant Gates did not answer whether Trileptal is an FDA-authorized pain 18 management medication. Plaintiff claims Defendant Gates’ response was deflective with 19 omissions. 20 Plaintiff claims that contrary to the posture of Defendants Cryer, Gates and Doe Defendants, 21 Trileptal is not an FDA-authorized drug to treat pain. Plaintiff cites to release notice in 2010 stating 22 that the only authorized us for Trileptal is for treatment of epilepsy and there was a settlement for 23 promoting Trileptal for use to treat pain.1 Plaintiff further alleges that into 2016 and beyond, the 24 FDA published information related to Trileptal informing CDCR health care providers and officials 25 to properly train doctors. Plaintiff asserts that Defendants Cryer and Gates were required to ensure 26 that Doe Defendants were properly trained. Plaintiff claims that defendants continue to prescribe 27

28 1 Plaintiff cites to exhibits not attached to the complaint. 1 Oxcarbazepine. 2 Based on these allegations, Plaintiff asserts claims against Defendants Cryer and Gates 3 based on their failure to adequately train prison doctors, deliberate indifference against Defendants 4 Does 1 through 5, and emotional distress. 5 Claim II 6 In Claim II, Plaintiff alleges that he arrived at CSATF on March 9, 2017, to receive care for 7 groin pain. After seven months of seeking pain relief, Plaintiff filed a CDCR 602 Health Care 8 appeal alleging deliberate indifference and retaliation for prior exercise of his First Amendment 9 rights. In his appeal, Plaintiff explained the pain he suffered, the ineffective psychotropic drugs to 10 treat his pain, and the requests for referrals to specialists that were denied. Plaintiff contends that 11 due to the inadequate pain management treatment, he suffered horrific pain that caused him to 12 double over, fall to the ground injuring his head and arm or freezing like a statue. 13 Plaintiff submitted a CDCR 7362 medical requests seeking prescription of Neurontin, a pain 14 management drug, which suppressed all types of pain that Plaintiff suffered while on a prior 15 prescription.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United Mine Workers of America v. Gibbs
383 U.S. 715 (Supreme Court, 1966)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
City of Canton v. Harris
489 U.S. 378 (Supreme Court, 1989)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Simmons v. Navajo County, Ariz.
609 F.3d 1011 (Ninth Circuit, 2010)
Barbara P. Hutchinson v. United States of America
838 F.2d 390 (Ninth Circuit, 1988)
Silva v. Di Vittorio
658 F.3d 1090 (Ninth Circuit, 2011)
Doxsee Sea Clam Co., Inc. v. Christian Brown
13 F.3d 550 (Second Circuit, 1994)
Anderson v. County of Kern
45 F.3d 1310 (Ninth Circuit, 1995)
Mabe v. San Bernardino County
237 F.3d 1101 (Ninth Circuit, 2001)
Toguchi v. Soon Hwang Chung
391 F.3d 1051 (Ninth Circuit, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
(PC) Legare v. Cryer, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pc-legare-v-cryer-caed-2019.